On March 12, 2018, UACT joined 15 other organizations in the United States and Korea in a letter to the United States Trade Representative, urging the administration to ignore the wishes of pharmaceutical lobbyists and to not interfere with patient access to medicines in Korea. Recently, Korea has passed legislation aimed at lowering drug prices and increasing the government’s negotiating power. Pharmaceutical corporations have taken notice, and through the industry lobbyist group PhRMA (Pharmaceutical Research and Manufacturers of America), have pressured the U.S. government to retaliate against the country in trade negotiations. In its submission to the USTR’s yearly “Special 301” review of intellectual property protection in otherRead More →